Last reviewed 2026-04-20 · How we verify

Securpres (INDENOLOL)

Phase 2 active Small molecule

Securpres (generic name: INDENOLOL) is a indenolol drug. It is currently in Phase 2 development.

Securpres works by blocking the beta-1 adrenergic receptor, which reduces the heart's workload and slows heart rate.

Securpres, also known as indenolol, is a small molecule drug that targets the beta-1 adrenergic receptor. It is classified as an indenolol, a type of beta-blocker. However, there is limited information available on its commercial status, approved indications, and pharmacokinetic properties. As a result, its use and safety profile are not well established. Further research is needed to fully understand the potential benefits and risks of Securpres.

Likelihood of approval

13.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Cardiovascular Phase 3 risk -2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	INDENOLOL
Drug class	indenolol
Target	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

Imagine your heart is like a racing car engine. The beta-1 adrenergic receptor is like the accelerator pedal. When it's stimulated, the engine revs up and the heart beats faster. Securpres is like a brake that slows down the engine, reducing the heart's workload and helping to control conditions like high blood pressure or heart failure.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Securpres CI brief — competitive landscape report
Securpres updates RSS · CI watch RSS

Frequently asked questions about Securpres

What is Securpres?

Securpres (INDENOLOL) is a indenolol drug.

How does Securpres work?

Securpres works by blocking the beta-1 adrenergic receptor, which reduces the heart's workload and slows heart rate.

What is the generic name of Securpres?

INDENOLOL is the generic (nonproprietary) name of Securpres.

What drug class is Securpres in?

Securpres belongs to the indenolol class. See all indenolol drugs at /class/indenolol.

What development phase is Securpres in?

Securpres is in Phase 2.

What does Securpres target?

Securpres targets Beta-1 adrenergic receptor, Beta-2 adrenergic receptor and is a indenolol.

Drug class: All indenolol drugs
Target: All drugs targeting Beta-1 adrenergic receptor, Beta-2 adrenergic receptor
Therapeutic area: All drugs in Cardiovascular

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing